Q1 2026 CVRx Inc Earnings Call Transcript

May 11, 2026 / 08:30 PM GMT

Release Date Price: $6.92 (+1.32%)

Transcript 10-Q8-K

Key Points

Positve

CVRx Inc (CVRX) exceeded the high end of their guidance range with a 22% growth in the United States.
The transition to Category 1 CPT codes has significantly advanced reimbursement, with a 46% approval rate for Medicare Advantage prior authorizations in Q1 2026.
The BENEFIT-HF trial, if successful, could expand the addressable market from 339,000 to over 980,000 patients, potentially tripling the market opportunity to $30 billion.
Gross margin increased to 87% from 84% a year ago, driven by higher average selling prices and improved manufacturing efficiencies.
The company has made meaningful progress in therapy awareness and clinical evidence, with a strong presence at cardiology meetings and the initiation of the BENEFIT-HF trial.

Negative

The reimbursement environment faced challenges with new regulations causing higher initial denial rates, particularly in March.
Revenue generated in Europe decreased by 2%, with a decline in revenue units from 59 to 56.
Net loss for Q1 2026 was $13.1 million, slightly improved from a $13.8 million loss in Q1 2025, but still significant.
R&D expenses increased by 23% to $3.1 million, driven by higher consulting and compensation expenses.
The company is cautious about the timeline for the BENEFIT-HF trial, which could take 5-7 years to complete, delaying potential market expansion.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CVRX.OQ - CVRx Inc
Q1 2026 CVRx Inc Earnings Call
May 11, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings, and welcome to the CVRX Q1 2026 earnings call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. Should anyone require operator assistance during the conference, please press *0 on your telephone keypad. As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Mike Vallee, from ICR Healthcare.

Thank you. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon.

Thank you for joining us today for CBRX's first quarter 2026

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.